Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting

REDWOOD CITY, Calif. & BOSTON --(BUSINESS WIRE)--Nov. 2, 2023-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65 th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023 . Details of the poster presentation are as follows: Title : Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma Poster Number: 3478 Session Name : 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II Presenting Author: Monica Moreno , Ph.D. Date/Time: Sunday, December 10, 2023 , from 6:00 - 8:00 p.m. PDT About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20231102190660/en/ Adicet Bio., Inc. Investor and Media Contacts Anne Bowdidge [email protected] Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200 [email protected] Source: Adicet Bio, Inc.

The release as fetched from its publisher. adicetbio.com ↗